Literature DB >> 4027151

Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects.

B C Campbell, A W Kelman, W S Hillis.   

Abstract

Calcium antagonists reduce myocardial contractility in vitro. Nicardipine is a dihydropyridine derivative with enhanced selectivity for vascular smooth muscle. We have studied the pharmacokinetics and the haemodynamic effects that occur in man following bolus intravenous administration of nicardipine. Ten normotensive male subjects received either nicardipine or placebo i.v., allocated in a randomised double-blind manner, over 60s. Plasma nicardipine concentration, blood pressure, heart rate, and systolic time intervals were measured before dosing and at frequent intervals between 1 and 360 min post dosing. At 160 micrograms kg-1, adequate plasma levels of nicardipine were obtained to permit analysis of individual pharmacokinetic variables, and significant and consistent haemodynamic effects were seen. After injection of nicardipine, systolic BP and the QS2 (measure of total electromechanical systole) and QT intervals were not altered. The changes in BP and heart rate were consistent with arteriolar vasodilatation. The changes in PEP and LVET suggest an increase in cardiac contractility, which is unlikely to be a direct effect of nicardipine on the myocardium but rather a result of afterload reduction. The close correlation of nicardipine plasma level with haemodynamic effect should permit accurate dose titration. The net increase in contractility should allow nicardipine to be administered safely with beta-adrenoceptor blocking drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027151      PMCID: PMC1400767          DOI: 10.1111/j.1365-2125.1985.tb05143.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Effect of verapamil on the noraml action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers.

Authors:  P F Cranefield; R S Aronson; A L Wit
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

2.  A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function.

Authors:  B N Singh
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

3.  Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Authors:  A Iliopoulou; P Turner; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

4.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  The prediction of individual systolic time interval v heart rate regression equations.

Authors:  A W Kelman; D J Sumner; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

6.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma.

Authors:  A T Wu; I J Massey; S Kushinsky
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

9.  Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.

Authors:  R W Millard; D A Lathrop; G Grupp; M Ashraf; I L Grupp; A Schwartz
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

10.  Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.

Authors:  V B Subramanian; A Lahiri; R Paramasivan; E B Raftery
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

  10 in total
  10 in total

Review 1.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

4.  Comparison of nicardipine and propranolol in the treatment of mild and moderate hypertension.

Authors:  V A Naukkarinen; K Karppinen; S Sarna
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Prediction of Tissue-Plasma Partition Coefficients Using Microsomal Partitioning: Incorporation into Physiologically based Pharmacokinetic Models and Steady-State Volume of Distribution Predictions.

Authors:  Kimberly Holt; Min Ye; Swati Nagar; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

6.  High-dose intra-arterial nicardipine results in hypotension following vasospasm treatment in subarachnoid hemorrhage.

Authors:  Neil Rosenberg; Marc A Lazzaro; Demetrius K Lopes; Shyam Prabhakaran
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

Review 7.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

8.  Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.

Authors:  T J Walley; A M Heagerty; K L Woods; R F Bing; J E Pohl; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

9.  Indirect portography enhanced by nicardipine versus prostaglandin E1.

Authors:  Y Inoue; H Nakamura; H Akaji; K Yamasaki
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Mar-Apr       Impact factor: 2.740

10.  Pharmacokinetic delivery and metabolizing rate of nicardipine incorporated in hydrophilic and hydrophobic cyclodextrins using two-compartment mathematical model.

Authors:  Sergey Shityakov; Carola Förster
Journal:  ScientificWorldJournal       Date:  2013-12-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.